Patents by Inventor CHENGANG XIANG

CHENGANG XIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11613735
    Abstract: A method for inducing reprogramming of a cell of a first type which is not a non-hepatocyte (non-hepatocyte cell), into a cell with functional hepatic drug metabolizing and transporting capabilities, is disclosed. The non-hepatocyte is induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte cell culture medium and hepatocyte maturation medium for a sufficient period of time to convert the non-hepatocyte cell into a cell with hepatocyte-like properties. The iHeps induced according to the methods disclosed herein are functional induced hepatocytes (iHeps) in that they express I and II drug-metabolizing enzymes and phase III drug transporters and show superior drug metabolizing activity compared to iHeps obtained by prior art methods. The iHeps thus provide a cell resource for pharmaceutical applications.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: March 28, 2023
    Assignees: BeiHao Stem Cell and Regenerative Medicine Translational Research Institute, Peking University, Beijing Vitalstar Biotechnology Co., Ltd.
    Inventors: Hongkui Deng, Yuanyuan Du, Yan Shi, Jun Jia, Jinlin Wang, Chengang Xiang, Nan Song, Jun Xu, Ming Yin
  • Publication number: 20220135941
    Abstract: Provided are compositions for long-term maintenance of functional hepatocytes in culture, a method for improved maintenance of functional hepatocytes in vitro, and functional hepatocytes cultures according to the methods. The culture compositions include at least: one activator of adenylate cyclase, one TGF? inhibitor, one Notch inhibitor, one Wnt inhibitor, and/or one BMP inhibitor. The combinations of compounds are added to any hepatocyte cell culture medium in an effective amount to maintain functional hepatocyte function in vitro, long term. The hepatocytes can be used for in vitro drug research and to model liver disease.
    Type: Application
    Filed: February 26, 2019
    Publication date: May 5, 2022
    Inventors: Hongkui Deng, Chengang Xiang, Yuanyuan Du
  • Publication number: 20170218333
    Abstract: A method for inducing reprogramming of a cell of a first type which is not a non-hepatocyte (non-hepatocyte cell), into a cell with functional hepatic drug metabolizing and transporting capabilities, is disclosed. The non-hepatocyte is induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte cell culture medium and hepatocyte maturation medium for a sufficient period of time to convert the non-hepatocyte cell into a cell with hepatocyte-like properties. The iHeps induced according to the methods disclosed herein are functional induced hepatocytes (iHeps) in that they express I and II drug-metabolizing enzymes and phase III drug transporters and show superior drug metabolizing activity compared to iHeps obtained by prior art methods. The iHeps thus provide a cell resource for pharmaceutical applications.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 3, 2017
    Inventors: Hongkui Deng, Yuanyuan Du, Yan Shi, Jun Jia, Jinlin Wang, Chengang Xiang, Nan Song, Jun Xu, Ming Yin
  • Publication number: 20100093090
    Abstract: The present invention relates to method or kit for efficient reprogramming of somatic cells.
    Type: Application
    Filed: September 28, 2009
    Publication date: April 15, 2010
    Applicants: PEKING UNIVERSITY, BEIJING HUA YUAN BO CHUANG TECHNOLOGY CO., LTD.
    Inventors: HONGKUI DENG, YANG ZHAO, XIAOLEI YIN, QIANG ZHANG, FANGFANG ZHU, HAISONG LIU, WEIFENG YANG, CHENGANG XIANG, HAN QIN